loading
전일 마감가:
$4.79
열려 있는:
$4.79
하루 거래량:
401.04K
Relative Volume:
0.88
시가총액:
$279.35M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
90.46
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
-0.84%
1개월 성능:
+2.82%
6개월 성능:
+7.73%
1년 성능:
-22.93%
1일 변동 폭
Value
$4.71
$4.835
1주일 범위
Value
$4.60
$4.95
52주 변동 폭
Value
$3.8092
$6.26

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
명칭
Vanda Pharmaceuticals Inc
Name
전화
202-734-3400
Name
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
직원
368
Name
트위터
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
VNDA's Discussions on Twitter

VNDA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VNDA
Vanda Pharmaceuticals Inc
4.74 282.30M 192.64M 2.51M 12.42M 0.0524
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-31 개시 H.C. Wainwright Buy
2024-07-11 개시 Cantor Fitzgerald Overweight
2022-02-25 다운그레이드 Jefferies Buy → Hold
2021-05-12 개시 BofA Securities Buy
2021-01-14 다운그레이드 Citigroup Buy → Neutral
2020-10-29 업그레이드 Citigroup Neutral → Buy
2020-06-09 다운그레이드 Citigroup Buy → Neutral
2020-03-16 다운그레이드 Oppenheimer Perform → Underperform
2020-03-12 업그레이드 Citigroup Neutral → Buy
2019-11-07 다운그레이드 Citigroup Buy → Neutral
2019-08-01 업그레이드 Citigroup Neutral → Buy
2019-07-25 다운그레이드 Stifel Buy → Hold
2018-12-11 다운그레이드 Oppenheimer Outperform → Perform
2018-12-04 업그레이드 Cantor Fitzgerald Neutral → Overweight
2018-12-04 재확인 Jefferies Buy
2018-11-08 재개 Jefferies Buy
2018-09-21 재개 Oppenheimer Outperform
2018-05-23 개시 Citigroup Buy
2018-01-19 개시 Seaport Global Securities Buy
2017-09-14 재확인 Piper Jaffray Overweight
2017-06-27 재개 Piper Jaffray Overweight
2017-05-26 개시 H.C. Wainwright Buy
2017-04-12 개시 Oppenheimer Outperform
2016-11-09 개시 Aegis Capital Buy
2016-10-06 재개 Jefferies Buy
모두보기

Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스

pulisher
Jul 25, 2025

Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com

Jul 24, 2025
pulisher
Jul 23, 2025

Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks

Jul 17, 2025
pulisher
Jul 09, 2025

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com

Jul 09, 2025
pulisher
Jun 30, 2025

Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 17, 2025

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360

Jun 13, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow

Jun 09, 2025
pulisher
Jun 05, 2025

Vanda Approves Key Proposals at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
May 29, 2025

Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360

May 29, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire

May 27, 2025
pulisher
May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025
pulisher
May 27, 2025

Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360

May 22, 2025
pulisher
May 22, 2025

Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow

May 21, 2025

Vanda Pharmaceuticals Inc (VNDA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):